A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis- associated liver disease

Hepatology

Volumn 27, Issue 1, 1998, Pages 166-174

  Lindblad, A ^a   Glaumann, H ^a   Strandvik, B ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; URSODEOXYCHOLIC ACID;

ADOLESCENT; ADULT; ARTICLE; BILE FLOW; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTIC FIBROSIS; DRUG EFFECT; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN PRODUCTION; LIVER BIOPSY; LIVER DISEASE; LIVER FUNCTION; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0031982747     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510270126     Document Type: Article

References (45)

1. 1 Roy CC, Weber AM, Morin CL, Lepage G, Brisson G, Yousef I, Lasalle R. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982 ; 1: 469–478. MEDLINE
2. 2 Oppenheimer E, Esterly J. Hepatic changes in young infants with cystic fibrosis: possible relation to focal biliary cirrhosis. J Pediatr 1975 ; 86: 683–689. MEDLINE
3. 3 Gaskin K, Donna L, Waters R, Howman‐Giles R, De Silva M, Earl JW, Martin HCO, et al. Liver disease and common bile duct stenosis in cystic fibrosis. N Engl J Med 1988 ; 318: 340–346. MEDLINE
4. 4 Strandvik B, Hjelte L, Gabrielsson N, Glaumann H. Sclerosing cholangitis in cystic fibrosis. Scand J Gastroenterol 1988 ; 23 (Suppl 143: 121–124. MEDLINE
5. 5 Maurage C, Lenaerts C, Weber A, Brochu P, Yousef I, Roy C. Meconium ileus and its equivalent as a risk factor for the development of cirrhosis: an autopsy study in cystic fibrosis. J Pediatr Gastroenterol Nutr 1989 ; 9: 17–20. MEDLINE
6. 6 May GR, Sutherland LR, Shaffer EA. Efficacy of bile acid therapy for gallstone dissolution: a meta‐analysis of randomized trials. Aliment Pharmacol Ther 1993 ; 7: 139–148. MEDLINE
7. 7 Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. Eur J Clin Pharmacol 1991 ; 40: 473–476. MEDLINE
8. 8 Poupon R, Balkau B, Eschwège E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. the UDCA‐PBC Study Group. N Engl J Med 1991 ; 324: 1548–1554. MEDLINE
9. 9 Attili A, Rusticali A, Varriale M, Carli L, Repice A, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12‐month double‐blind, placebo‐controlled trial. J Hepatol 1994 ; 20: 315–320. MEDLINE
10. 10 Poupon R, Poupon R, Balkau B. Ursodiol for the long‐term treatment of primary biliary cirrhosis. the UDCA‐PBC study group. N Engl J Med 1994 ; 330: 1342–1347. MEDLINE
11. 11 Cotting J, Lentzte M, Reichen J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990 ; 31: 918–921. MEDLINE
12. 12 Galabert C, Montet J, Lengrand D, Lecuire A, Sotta C, Figarella C, Chazalette JP. Effects of ursodeoxycholic acid on liver function in patients with cystic fibrosis and chronic cholestasis. J Pediatr 1992 ; 121: 138–141. MEDLINE
13. 13 Colombo C, Setchell K, Podda M, Crosignani A, Roda A, Curcio L, Ronchi M, et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J Pediatr 1990 ; 117: 482–489. MEDLINE
14. 14 Colombo C, Castellani M, Balistreri W, Seregni E, Assaisso M, Giunta A. Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease. Hepatology 1992 ; 15: 677–684. MEDLINE
15. 15 Dössing M, Poulsen HE, Andreasen PB, Tygstrup N. A simple method for determination of antipyrine clearance. Clin Pharmacol Ther 1982 ; 32: 392–396. MEDLINE
16. 16 Tygstrup N. Determination of the hepatic galactose elimination capacity after a single intravenous injection in man. Acta Physiol Scand 1963 ; 58: 162–172.
17. 17 Menghini G. One‐second needle biopsy of the liver. Gastroenterology 1958 ; 35: 190–199.
18. 18 Almé B, Bremmelgaard A, Sjövall J, Thomassen P. Analysis of metabolic profiles of bile acids in urine using a lipophilic anion exchanger and computerized gas‐liquid chromatography–mass spectrometry. J Lipid Res 1977 ; 18: 339–362. MEDLINE
19. 19 Marschall H, Griffiths W, Götze U, Zhang J, Wietholtz H, Busch N, Sjövall J, et al. The major metabolites of ursodeoxycholic acid in human urine are conjugated with N ‐acetylglucosamine. Hepatology 1994 ; 20: 845–853. MEDLINE
20. 20 Yamaga N, Kohara H. Conjugation types of 7β‐hydroxylated bile acids detected in healthy human urine. J Biochem 1994 ; 116: 1123–1126. MEDLINE
21. 21 Hultcrantz R, Mengarelli S, Strandvik B. Morphological findings in the liver of children with cystic fibrosis: a light and electron microscopical study. Hepatology 1986 ; 6: 881–889. MEDLINE
22. 22 Koopman BJ, Wolthers G, van der Molen JC, Nagel GT, Kruizinga W. Abnormal urinary bile acids in a patient suffering from cerebrotendinous xanthomatosis during oral administration of ursodeoxycholic acid. Biochim Biophys Acta 1987 ; 917: 238–246. MEDLINE
23. 23 Scott‐Jupp R, Lama M, Tanner MS. Prevalence of liver disease in cystic fibrosis. Arch Dis Child 1991 ; 66: 698–701. MEDLINE
24. 24 Craig J, Haddad H, Shwachman H. The pathological changes in the liver in cystic fibrosis of the pancreas. Pediatrics 1956 ; 18: 387–409.
25. 25 Bass S, Connon JJ, Ho CS. Biliary tree in cystic fibrosis: biliary tract abnormalities in cystic fibrosis demonstrated by endoscopic retrograde cholangiography. Gastroenterology 1983 ; 84: 1592–1596. MEDLINE
26. 26 Colombo C, Battezzati P, Podda M, Bettinardi N, Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double‐blind multicenter trial. The Italian group for the study of ursodeoxycholic acid in cystic fibrosis. Hepatology 1996 ; 23: 1484–1490. MEDLINE
27. 27 Colombo C, Crosignani A, Assaisso M, Battezzati PM, Podda M, Giunta A, Zimmer‐Nechemias L, et al. Ursodeoxycholic acid therapy in cystic fibrosis‐associated liver disease: a dose‐response study. Hepatology 1992 ; 16: 924–930. MEDLINE
28. 28 Leuschner U, Guldutuna S, Imhof M, Hübner K, Benjaminov A, Leuschner M. Effects of ursodeoxycholic acid after 4 to 12 years of therapy in early and late stages of primary biliary cirrhosis. J Hepatol 1994 ; 21: 624–633. MEDLINE
29. 29 Eklund A, Norman A, Strandvik B. Excretion of bile acids in healthy children and children with cystic fibrosis. Scand J Clin Lab Invest 1980 ; 40: 595–608. MEDLINE
30. 30 Roy C, Delage G, Fontaine A, Robitaille L, Chartrand L, Weber A, Morin C. The fecal microflora and bile acids in children with cystic fibrosis. Am J Clin Nutr 1979 ; 32: 2404–2409. MEDLINE
31. 31 Lefebvre D, Ratelle S, Chartrand L, Roy C. Reduced microbial transformation of bile acids in cystic fibrosis. Experientia 1977 ; 33: 616–618. MEDLINE
32. 32 Arborgh B, Eklund A, Norman A, Strandvik B. Urinary bile acid excretion in correlation to liver histopathology in cystic fibrosis. Scand J Gastroenterol 1980 ; 15: 73–80. MEDLINE
33. 33 Bremmelgaard A, Sjövall J. Bile acid profiles in urine of patients with liver disease. Eur J Clin Invest 1979 ; 9: 341–348. MEDLINE
34. 34 Dosanjh A, Lencer W, Brown D, Ausiello DA, Stow JL. Heterologous expression of ΔF508 CFTR results in decreased sialylation of membrane glycoconjugates. Am J Physiol 1994 ; 266: C360–C366. MEDLINE
35. 35 Stiehl A, Rudolph G, Raedsch R, Möller B, Hopf U, Lotterer E, Bircher J, et al. Ursodeoxycholic acid–induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis. Hepatology 1990 ; 12: 492–497. MEDLINE
36. 36 Poupon R, Chrétien Y, Poupon R, Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993 ; 17: 599–604. MEDLINE
37. 37 Crosignani A, Podda M, Battezzatti PM, Bertolino E, Zuin M, Watson D, Setchell KDR. Changes in bile acid composition in patients with primary biliary cirrhosis induced by ursodeoxycholic acid administration. Hepatology 1991 ; 14: 1000–1007. MEDLINE
38. 38 Fischer S, Neubrand M, Paumgartner G. Biotransformation of orally administered ursodeoxycholic acid in man as observed in gallbladder bile, serum and urine. Eur J Clin Invest 1993 ; 23: 28–36. MEDLINE
39. 39 Palmer R. Metabolism of lithocholate in humans. In: Back P, Gerok W, eds. Bile acids in Human Diseases. New York: F.K Schattauer. 1972: 65.
40. 40 Picciotto A, Ciravegna G, Lapertosa G, Celle G. Percutaneous or laparoscopic needle biopsy in the evaluation of chronic liver disease? Am J Gastroenterol 1984 ; 79: 567–568. MEDLINE
41. 41 Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis: therapeutic implications and long term follow up. Arch Dis Child 1993 ; 68: 653–657. MEDLINE
42. 42 Yoshikawa M, Tsujii T, Matsumura K, Yamao J, Matsumura Y, Kubo R, Fukui H, et al. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992 ; 16: 358–364. MEDLINE
43. 43 Lacaille F, Paradis K. The immunosuppressive effect of ursodeoxycholic acid: a comparative in vitro study on human peripheral blood mononuclear cells. Hepatology 1993 ; 18: 165–172. MEDLINE
44. 44 Hofmann A. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand J Gastroenterol 1994 ; 29 (Suppl 204: 1–15.
45. 45 Cirillo N, Zwas F. Ursodeoxycholic acid in the treatment of chronic liver disease. Am J Gastroenterol 1994 ; 89: 1447–1452. MEDLINE